Important update from NABP, a look at how DSCSA requirements could be utilized in a targeted way to help stay ahead of counterfeiters and bad actors.
Associate Executive Director, Government Affairs and Innovation at National Association of Boards of Pharmacy
🚀 Exciting News! 🚀 I’m thrilled to announce the release of the National Association of Boards of Pharmacy® (NABP®) Serial Number Decommissioning Pilot Report. This report marks a significant milestone in our mission to enhance the security of the prescription drug supply chain and protect patients. Key Highlights: - The Drug Supply Chain Security Act (DSCSA) has made strides in reducing dangerous medicines but has a critical gap: the lack of capturing the end of active status of serial numbers. - Our exploratory pilot with manufacturers and dispensers shows that this vulnerability can be addressed, focusing on the most vulnerable products and scenarios. - Collaboration with the industry, centered on patient safety, is essential to create the right incentives for adoption. The DSCSA mandates serialization down to the saleable unit, facilitating data exchange and supporting tools like product verification and tracing. However, limitations in these tools allow criminals to exploit the system and insert counterfeit medications into the legitimate supply chain. In response, NABP organized a voluntary pilot to explore decommissioning serial numbers as a strategy to prevent and detect counterfeit medicines. This pilot, using Pulse by NABP, is the first step in a larger effort to collaborate across the supply chain to protect patients. We encourage you to review the report and reach out with any questions. Stay tuned for more updates as we move into 2025. Together, we can strengthen our defenses against counterfeit medications and ensure the safety and integrity of our supply chain. https://lnkd.in/e2XwPTsG #Pharmacy #Healthcare #PatientSafety #DSCSA #SupplyChainSecurity #NABP